A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: iStock
An estimated 370,000 people developed rifampicin-resistant tuberculosis (RR-TB) worldwide in 2025, highlighting the continuing threat of drug-resistant TB, according to the World Health Organization (WHO).
The Global Tuberculosis Report 2026 showed a gradual decline in RR-TB since 2015. However, major gaps in diagnosis and treatment persist.
Only 155,333 people were diagnosed with RR-TB and started treatment in 2025, just 42% of the estimated number who developed the disease.
Drug-resistant TB occurs when bacteria become resistant to one or more medicines. Rifampicin resistance is particularly concerning because rifampicin is a key first-line TB drug.
Also read: Global TB Deaths Fall 35% Since 2015, But 2030 Target Remains Distant: WHO
The proportion of new TB cases involving rifampicin resistance fell from 4.4% in 2015 to 3.1% in 2025.
Resistance remained higher among previously treated patients: 14.8% had RR-TB in 2025, down from 20% in 2015.
China, India, the Philippines and the Russian Federation together accounted for more than half of estimated global RR-TB cases in 2025.
Eastern Europe and Central Asia reported the highest proportions of RR-TB among previously treated patients, exceeding 50%.
India was also among five countries — alongside China, Indonesia, Pakistan and the Philippines — that accounted for about 60% of the global gap between estimated RR-TB cases and people enrolled on treatment.
Rifampicin-resistant TB is listed in WHO's Bacterial Priority Pathogens List under the critical group.
WHO identifies two main drivers of multidrug- and rifampicin-resistant TB (MDR/RR-TB): inappropriate treatment and person-to-person transmission.
Incorrect use of TB medicines, poor-quality formulations, improper storage and premature treatment stoppage can contribute to drug resistance.
Resistant bacteria can also spread between people. Those with pulmonary TB can transmit the infection through coughing, sneezing or talking. Others become infected by inhaling airborne bacteria.
Timely diagnosis, appropriate treatment and infection prevention are particularly important in crowded settings such as hospitals and prisons.
Read More: 15 Lakh Asymptomatic TB Cases Detected In India: How TB Mukt Bharat Abhiyaan Is Driving Screening
The treatment success rate for RR-TB reached 70% among patients who started treatment in 2023, the latest year with available outcome data.
This was below the 71% recorded in 2022 but above the rates in 2021 (68%), 2020 (64%) and 2012 (50%).
By comparison, treatment success for drug-susceptible TB is about 90%, according to WHO.
Across WHO regions, RR-TB treatment success ranged from 56% in the Region of the Americas to 77% in the African Region.
WHO recommends all-oral regimens for drug-resistant TB, including shorter courses for eligible patients. Six-month regimens accounted for 42% of RR-TB treatment in 2025, up from 18% in 2024 and 3% in 2023.
By the end of 2025, 106 countries were using these regimens, compared with 98 in 2024 and 60 in 2023.
They were the most frequently used treatment option in five of the six WHO regions. Uptake was highest in the Eastern Mediterranean (72%) and African (65%) regions.
Europe was the only region where longer regimens remained the main option for a large share of patients (76%).
WHO recommends the six-month BPaLM regimen — bedaquiline, pretomanid, linezolid and moxifloxacin — for eligible patients with MDR/RR-TB.
Treatment choices depend on drug resistance, previous exposure to TB medicines and other clinical factors.
Expanding access to rapid drug-resistance testing, starting treatment promptly and preventing transmission remain key to tackling drug-resistant TB.
Credit: AI image
There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline.
An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.
The experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.
Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.
The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.
The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.
Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.
They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.
Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.
Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.
Diranersen works differently by targeting tau production rather than amyloid accumulation.
Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study
Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up.
Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.
Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.
Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.
Credit: AI
India is set to launch its first indigenously developed vaccine against H5N1 bird flu virus in chickens on November 20, as new outbreaks have been emerging in different parts of the country.
Developed by scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the inactivated vaccine targets H5N1 Clade 2.3.2.1a, a strain that caused several bird flu outbreaks among chickens in India.
According to the Ministry of Agriculture and Farmers' Welfare, this marks a significant development in poultry and public health as there is no commercial vaccine against this particular H5N1 strain.
Bird flu, medically known as avian influenza, is a viral infection that primarily affects birds. Highly pathogenic avian influenza (HPAI) strains, including H5N1, can cause severe illness and extremely high mortality among infected poultry.
Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving H5N1 and H5N8 subtypes.
These outbreaks can have serious economic consequences. Infected birds may need to be culled to prevent further transmission. The 2006 outbreak alone resulted in estimated direct and indirect losses of Rs 2,200–3,000 crore.
The newly developed vaccine can help strengthen the country’s ability to prevent outbreaks and protect poultry populations against the H5N1 strain currently circulating in the country.
Also read: UK Reports Its First Human Case Of Bird Flu
The indigenous vaccine contains an inactive version of the virus that cannot replicate and infect. When administered, it exposes the chicken's immune system to viral components, just enough to allow it to recognise the virus and develop an immune response.
If the vaccinated bird encounters the actual virus later, its immune system can recognise it and respond more effectively.
The vaccine announcement comes just as fresh reports of bird flu infections in poultry have emerged.
In Tamil Nadu's Cuddalore district, H5N1 infections were confirmed following sudden deaths among chickens at poultry farms. More than 35,000 birds had died by November 13, prompting authorities to initiate containment and culling efforts.
Andhra Pradesh has also reported H5N1 infections in poultry, prompting restrictions and surveillance measures.
The indigenous vaccine is an important step in India's poultry disease-control efforts, but its introduction does not mean bird flu outbreaks will be prevented completely.
Its effectiveness depends on vaccination coverage, administration, monitoring of viral strains and compliance with farm biosecurity measures.
Also read: New Strain Of Bird Flu Detected In US, Here’s How You Can To Stay Protected
Although H5N1 primarily affects birds, the virus can occasionally cross the zoonotic barrier and infect humans, especially those who have long-term contact with infected birds, their secretions or contaminated environments.
Human infections can cause symptoms ranging from mild respiratory illness to severe pneumonia and, in some cases, death.
According to the World Health Organization (WHO), 1,003 human cases of H5N1 infection, including 479 deaths, had been reported across 25 countries since 2003, as cited in the Indian government's November 18 announcement.
Human infections, however, remain relatively uncommon and sustained human-to-human transmission has not been established.
People working with poultry should avoid handling sick or dead birds without protective equipment. Unusual bird deaths should be reported to veterinary authorities.
© $2026 Times Horizon Private Limited